Biomendex
About:
The first adaptive bone graft substitute in the world.
Website: http://www.biomendex.com/
Top Investors: European Innovation Council
Description:
Biomendex develops and manufactures adaptable synthetic bone substitute materials for bone regeneration. Their invention, Adaptos®, is the first bioactive bone graft substitute that surgeons can cut, shape or squeeze into place. It is the only bone graft substitute that mimics bone by being resilient and bioactive. Adaptos® bone graft substitutes are being developed for clinical and veterinary use.
Total Funding Amount:
2.25M EUR
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
Tampere, Western Finland, Finland
Founded Date:
2018-01-01
Founders:
Kaarlo Paakinaho
Number of Employees:
1-10
Last Funding Date:
2019-09-20
IPO Status:
Private
Industries:
© 2025 bioDAO.ai